What used to be a mysterious new variant first detected in the UK is now the most dominant coronavirus strain in the US. And unlike the original strain of the novel coronavirus, the more contagious B.1.1.7 strain is hitting young people particularly hard.
Numerous variants of SARS-CoV-2-harboring mutations in spike have arisen globally
mRNA vaccines elicit potent neutralizing activity against homologous pseudovirus
The CDC is finalizing new guidelines for doctors on long-haul COVID-19.
Long-haul COVID-19 patients face many health threats — including a higher chance of dying — up to 6 months after they catch the virus, according to a massive study published in the journal Nature.
There’s nothing new about fake news. For as long as there has been news, there has been misinformation, both deliberate and unintentional.
Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.
The clinical impact of the new
SARS-CoV-2 lineage B.1·1.7 on children
and young people (aged 18 years or
younger) regarding acute respiratory
COVID-19 is yet to be fully defined.
Media reports of increases in admissions
to hospital and more serious illness in
children and young people have resulted
in public confusion and implicated the
B.1.1.7 variant as a more pathogenic
infection within this group. This
uncertainty has necessitated a public
statement from the Royal College of
Paediatrics and Child Health.
Many people with long COVID feel that science is failing them. Neglecting them could make the pandemic even worse.
We analysed issues concerning the establishment of compulsory vaccination against COVID-19, as well as the role of misinformation as a disincentive—especially when published by health professionals—and citizen acceptance of measures in this regard. Data from different surveys revealed a high degree of hesitation rather than outright opposition to vaccines.
The novel mRNA vaccines of Moderna and Pfizer/BioNTech are among the most effective of all the developed vaccines at preventing infection and disease. For that, we are all grateful. But even the best vaccines fail to protect some people some of the time. The clinical trial data from both the Pfizer/BioNTech and the Moderna shows they are around 95% effective, which means that 5% of those fully vaccinated are still at risk for infection even a short time following the complete dose, when the vaccines are thought to be maximally effective.